These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16294183)

  • 41. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
    Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G
    Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pulmonary hypertension and right ventricular failure. Part XIV. Differentiated therapy of primary (idiopathic) and associated forms of pulmonary arterial hypertension].
    Batyraliev TA; Ekinsi E; Pataraia SA; Pershukov IV; Sidorenko BA; Preobrazhenskiĭ DV
    Kardiologiia; 2008; 48(3):78-84. PubMed ID: 18429760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to bosentan in children with pulmonary hypertension.
    Maiya S; Hislop AA; Flynn Y; Haworth SG
    Heart; 2006 May; 92(5):664-70. PubMed ID: 16216850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of pulmonary arterial hypertension: a step forward.
    Sharma S
    Chest; 2003 Jul; 124(1):8-11. PubMed ID: 12853493
    [No Abstract]   [Full Text] [Related]  

  • 45. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
    Ruopp NF; Cockrill BA
    JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment of pulmonary arterial hypertension associated to systemic sclerosis].
    Hachulla E
    Rev Med Interne; 2004 Mar; 25(3):195-200. PubMed ID: 15049280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.
    Oldfield V; Lyseng-Williamson KA
    Am J Cardiovasc Drugs; 2006; 6(3):189-208. PubMed ID: 16780392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pulmonary arterial hypertension in connective tissue disease].
    Cottin V
    Rev Mal Respir; 2006 Sep; 23(4 Suppl):13S61-72. PubMed ID: 17057632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacotherapeutic management of pulmonary arterial hypertension.
    Anderson JR; Nawarskas JJ
    Cardiol Rev; 2010; 18(3):148-62. PubMed ID: 20395700
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Endothelin receptor antagonist].
    Kishi T; Sunagawa K
    Nihon Rinsho; 2008 Nov; 66(11):2152-6. PubMed ID: 19051735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension.
    Shimizu M; Imanishi J; Takano T; Miwa Y
    Intern Med; 2011; 50(20):2341-6. PubMed ID: 22001462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pulmonary arterial hypertension: changing approaches to management].
    Sidorenko BA; Preobrazhenskiĭ DV; Batyraliev TA; Belenkov IuN
    Kardiologiia; 2011; 51(1):100-8. PubMed ID: 21626809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The management of acute pulmonary arterial hypertension.
    Hui-li G
    Cardiovasc Ther; 2011 Jun; 29(3):153-75. PubMed ID: 20560976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Cheng J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treating pulmonary hypertension in pediatrics.
    Lador F; Sekarski N; Beghetti M
    Expert Opin Pharmacother; 2015 Apr; 16(5):711-26. PubMed ID: 25665593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.